Heme-Oxygenase 1 Mediated Activation of Cyp3A11 Protects Against Non-Steroidal Pain Analgesics Induced Acute Liver Damage in Sickle Cell Disease Mice
Open Access
Abstract
Pain constitutes a significant comorbidity associated with sickle cell disease (SCD). Analgesics serve as the primary method for pain management; however, the long-term effects of these drugs on the liver of SCD patients remain not completely understood. Using real-time intravital imaging, we analyzed the effect of non-steroidal analgesics (NSA) in the liver of control and SS (SCD) mice. Remarkably, we found completely opposing effects in the liver of control and SS mice post-NSA treatment. Whereas SS mice were able to better tolerate the NSA treatment acutely compared to their littermate controls, in the long term, these mice showed delayed resolution of liver injury and exacerbated fibrosis compared to control mice. Mechanistically, we found that SS mice were protected from cytotoxicity caused by NSA at baseline due to the significant activation of hepatic Kupffer cells, which produced heme-oxygenase 1 (HO-1). HO-1 promoted the activation of the cytoprotective enzyme Cyp3A11, which inhibited hepatic damage caused by NSA. However, in the long term, depletion of hepatic Kupffer cells led to reduced expression of HO-1, which blocked the activation of Cyp3A11, resulting in fibrosis and a delay in the resolution of liver injury and inflammation. These preclinical data provide a strong proof-of-concept for HO-1 as well as Cyp3A11 as cytoprotectors against NSA-induced liver damage in the Townes model of SCD and support further development of these compounds as potential novel therapies for end-organ damage in SCD.Keywords
Funding Information
- the American Society of Hematology junior faculty scholar award (R01HL128297, R01HL141080, R01HL166345, 18TPA34170588, 23TPA1074022)
- Versiti start-up fund (R01HL128297, R01HL141080, R01HL166345, 18TPA34170588, 23TPA1074022)
- National Heart, Lung, and Blood Institute Grants (R01HL128297, R01HL141080, R01HL166345, 18TPA34170588, 23TPA1074022)
- the American Heart Association Grants (R01HL128297, R01HL141080, R01HL166345, 18TPA34170588, 23TPA1074022)
This publication has 43 references indexed in Scilit:
- Heme oxygenase-1: A provenance for cytoprotective pathways in the kidney and other tissuesKidney International, 2006
- Heme oxygenase-1 is a modulator of inflammation and vaso-occlusion in transgenic sickle miceJournal of Clinical Investigation, 2006
- Dose‐ and time‐dependent oval cell reaction in acetaminophen‐induced murine liver injury†Hepatology, 2005
- Understanding pain and improving management of sickle cell disease: the PiSCES study.2005
- Pain management and symptoms of substance dependence among patients with sickle cell diseaseSocial Science & Medicine, 2003
- Different Faces of the Heme-Heme Oxygenase System in InflammationPharmacological Reviews, 2003
- Regulation of Heme Oxygenase-1 by Redox Signals Involving Nitric OxideAntioxidants & Redox Signaling, 2002
- Oxidative Stress and Induction of Heme Oxygenase-1 in the Kidney in Sickle Cell DiseaseThe American Journal of Pathology, 2001
- Mouse Cytochrome P450 (Cyp3a11): Predominant Expression in Liver and Capacity to Activate Aflatoxin B1Archives of Biochemistry and Biophysics, 1997
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaNew England Journal of Medicine, 1995